NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Ossianix

Ossianix

Private
Philadelphia, PennsylvaniaHealthcare & Life Scienceshttp://ossianix.com

Last Round

Grant

Jan 9, 2025

Total Funding Raised

$1.26M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Ossianix is a biotechnology company that provides a proprietary brain shuttle platform for the delivery of biotherapeutics across the Blood-Brain Barrier.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share, Government Contracts

AI Layer

Application

Keywords

brain shuttleblood-brain barrierBBBVNAR antibodiesantibody engineeringCNS drug deliveryshark antibodiesdrug delivery platformsingle-domain antibodiesbiologics deliverytransferrin receptor targetingcentral nervous system disordersCNStechnology licensingantibody discoveryphage display

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Ossianix Comparables

Compare Ossianix with similar companies based on industry and business-model similarity.

Ossianix comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Cenos Therapeutics
81%
JCR Pharmaceuticals Co., Ltd.
78%
ABL Bio, Inc.
78%

Ossianix Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJan 9, 2025
StrategicDec 16, 2014
Convertible DebtJan 3, 2012

Ossianix Investors

Notable investors and investment history

Ossianix investors
InvestorRounds
The ALS AssociationConvertible Debt, Seed
The Michael J. Fox Foundation for Parkinson's ResearchGrant
BioAdvance CapitalConvertible Debt, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 20, 2026

    Monthly visitors grew 130% MoM, reaching 1.9K.

  • Jan 9, 2025

    $1.26M grant from The Michael J. Fox Foundation

Ossianix Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Ossianix Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Ossianix's valuation, stock price, and market status.

Firmographic Details

HeadquartersPhiladelphia, Pennsylvania
Employee Range5
Year Founded2012
Last FundingJan 9, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.